The course of all lymphoma manifestations was evaluated on a whole-body CT.
The effect of epratuzumab on clinical manifestations was evaluated at 6, 10, and 18 weeks using numerical total BILAG scores as well as categorical scores.
The prevalences of autoantibodies and the clinical manifestations of PM/DM were evaluated comparing two cohorts in Mexico.
Study design Nine subjects who presented with fibrous dysplasia and were followed in orthopedic clinics were evaluated for other manifestations of MAS.
In addition, the period before clinical manifestation of infection and its duration were evaluated.
The cases were evaluated in terms of demographic data, associated diseases, clinical manifestations, CSF (cerebrospinal fluid) modifications and imagistic studies.
Nondiabetic, nonobese diabetic (NOD) mice aged 21 weeks were evaluated for salivary gland function, salivary gland inflammation and extraglandular disease manifestations.
The mice were evaluated to determine whether NIR dye binding correlated with arthritis manifestation, as assessed by footpad swelling.
Data were evaluated with analysis of variance (ANOVA) when comparing healthy controls with SLE patients or within the patient cohort when evaluating different disease manifestations.
The patients were evaluated for their (1) baseline characteristics, (2) radiographic analysis of the knee, (3) compliance with the treatment, (4) clinical manifestations, and (5) safety.
